[go: up one dir, main page]

GB0506967D0 - Novel crystalline salt - Google Patents

Novel crystalline salt

Info

Publication number
GB0506967D0
GB0506967D0 GBGB0506967.9A GB0506967A GB0506967D0 GB 0506967 D0 GB0506967 D0 GB 0506967D0 GB 0506967 A GB0506967 A GB 0506967A GB 0506967 D0 GB0506967 D0 GB 0506967D0
Authority
GB
United Kingdom
Prior art keywords
crystalline salt
novel crystalline
novel
salt
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0506967.9A
Other versions
GB2424880A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Priority to GB0506967A priority Critical patent/GB2424880A/en
Publication of GB0506967D0 publication Critical patent/GB0506967D0/en
Publication of GB2424880A publication Critical patent/GB2424880A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
GB0506967A 2005-04-06 2005-04-06 Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase Withdrawn GB2424880A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB0506967A GB2424880A (en) 2005-04-06 2005-04-06 Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0506967A GB2424880A (en) 2005-04-06 2005-04-06 Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase

Publications (2)

Publication Number Publication Date
GB0506967D0 true GB0506967D0 (en) 2005-05-11
GB2424880A GB2424880A (en) 2006-10-11

Family

ID=34586786

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0506967A Withdrawn GB2424880A (en) 2005-04-06 2005-04-06 Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase

Country Status (1)

Country Link
GB (1) GB2424880A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614279A2 (en) 2005-08-15 2012-11-06 Arrow Int Ltd crystalline and amorphous sodium atorvastatin
EP1924555B1 (en) 2005-08-15 2014-10-08 Arrow International Limited Process for the preparation of crystalline sodium atorvastatin
SI22255A (en) * 2006-04-14 2007-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New polymorphs of statine salts and their application in pharmaceutical formulations
WO2008053495A1 (en) * 2006-10-30 2008-05-08 Lupin Limited A novel crystalline form of atorvastatin sodium

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
FI94339C (en) * 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
CZ296967B6 (en) * 2002-02-01 2006-08-16 Zentiva, A.S. Process for preparing amorphous form of hemicalcium salt of (3R,5R)7-[3-phenyl-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropylpyrrol-l-yl]-3,5-dihydroxyheptanoic acid (atorvastatin)
AU2003295684A1 (en) * 2002-11-15 2004-06-15 Teva Pharmaceutical Industries Ltd. Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
WO2005014541A1 (en) * 2003-08-12 2005-02-17 Biocon Limited Novel antihypercholesterolemic compound
WO2005073187A1 (en) * 2004-01-28 2005-08-11 Apotex Pharmachem Inc. Improved process for the preparation of amorphous atorvastatin calcium
CA2666359A1 (en) * 2004-03-17 2005-10-06 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
ES2739493T3 (en) * 2004-05-05 2020-01-31 Pfizer Prod Inc Salt forms of atorvastatin with benetamine
JP2008510798A (en) * 2004-08-27 2008-04-10 バイオコン・リミテッド Method for amorphous atorvastatin calcium

Also Published As

Publication number Publication date
GB2424880A (en) 2006-10-11

Similar Documents

Publication Publication Date Title
AP2007004171A0 (en) Novel compounds
EP1868612A4 (en) Novel compounds
EP1868611A4 (en) Novel compounds
ZA200800522B (en) New salt II
IL186221A0 (en) Crystalline rosuvastatin intermediate
GB0512429D0 (en) Novel compound
ZA200806859B (en) Novel crystalline compounds
ZA200800515B (en) New Salt I
ZA200800488B (en) New Salt III
GB0506967D0 (en) Novel crystalline salt
EP1951257A4 (en) Crystalline forms
EP1951694A4 (en) Salt forms
GB0511000D0 (en) Novel salt
GB0501567D0 (en) Crystalline forms
GB0523845D0 (en) Novel salts
GB0427702D0 (en) Novel salt
HK1120044A (en) Salt forms
GB0501244D0 (en) Novel quaternised salt
HK1116193A (en) New salt ii
HK1119976A (en) Crystalline forms
GB0525350D0 (en) Novel compound
GB0522071D0 (en) Novel compound
GB0500406D0 (en) Novel compounds
GB0500925D0 (en) Novel compounds
GB0500285D0 (en) Novel compounds

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)